SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Sudeep Pharma Ltd

BSE: 544619 NSE: SUDEEPPHRM ISIN: INE0QPI01025
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Sudeep Pharma Ltd belong to?
Sudeep Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Sudeep Pharma Ltd a good quality company?
Sudeep Pharma Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Sudeep Pharma Ltd undervalued or overvalued?
Sudeep Pharma Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Sudeep Pharma Ltd a good buy now?
Sudeep Pharma Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Sudeep Pharma Ltd?
Sudeep Pharma Ltd revenue growth is 3.8% for FY-2025 , which is below its 5 year CAGR of 23.7% , indicating slower growth.
Q.2 Gross Profit margin of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 38% for FY-2025 , which is above its 5 year median of 23.7% , indicating increasing margins.
Q.3 Operating Profit Margin of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 37.33% for FY-2025 , which is above its 5 year median of 21.85% indicating increasing margins.
Q.4 Net Profit Margin of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Net Profit Margin is 26.84% for FY-2025 , is above with its 5 year median of 16.63%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 38 23.7
Operating Profit Margin 37.33 21.85
Net Profit Margin 26.84 16.63
Q.5 Return on Asset of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Return on Asset is 18.16%, which is below its 5 year historical median of 19.13%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Return on equity is 25.12% for FY-2025 , which is below its historical median of 34.32%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Return on capital employed is 28.72% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Cash conversion cycle is 155 days, above its historical median of 111 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.68 1.08
ROE 25.12 34.32
ROCE 28.72 37.02
Cash Conversion Cycle 155 days 111 days
Q.9 Debt to Equity ratio of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Debt-to-Equity ratio is 0.27 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Sudeep Pharma Ltd?
Sudeep Pharma Ltd Debt to cash flow from operations is 2 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Sudeep Pharma Ltd?
Promoters hold 76.15% of the Sudeep Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Sudeep Pharma Ltd vs industry peers?
Sudeep Pharma Ltd revenue CAGR is 23.73% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 356.7 137.1
Gross Profit 135.7 15.1
Operating Profit 133 16
Net Profit 96 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.68 0.8
ROE 25.12 8.91
ROCE 28.72 11.59
Cash Conversion Cycle (days) 154.99 76

Valuation & price assessment

Q.1 Stock return of Sudeep Pharma Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -
Q.3 Valuation ratios of Sudeep Pharma Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 74.83 88.35 40.28
Price to Book 9.32 17.98 2.77
Price to Sales 20.08 23.72 2.65
EV to EBITDA 51.18 60.42 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×